Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Individualized Dosing of Axitinib Based on First-Dose Area Under the Concentration-Time Curve for Metastatic Renal-Cell Carcinoma.
Miura Y, Imamura CK, Uchino K, Kishida T, Matsubara N, Shinojima T, Kondo K, Hongo F, Yoshimura K, Tanigawara Y, Takano T. Miura Y, et al. Among authors: tanigawara y. Clin Genitourin Cancer. 2019 Feb;17(1):e1-e11. doi: 10.1016/j.clgc.2018.09.015. Epub 2018 Sep 29. Clin Genitourin Cancer. 2019. PMID: 30529389 Clinical Trial.
CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study.
Tamura K, Imamura CK, Takano T, Saji S, Yamanaka T, Yonemori K, Takahashi M, Tsurutani J, Nishimura R, Sato K, Kitani A, Ueno NT, Mushiroda T, Kubo M, Fujiwara Y, Tanigawara Y. Tamura K, et al. Among authors: tanigawara y. J Clin Oncol. 2020 Feb 20;38(6):558-566. doi: 10.1200/JCO.19.01412. Epub 2019 Dec 10. J Clin Oncol. 2020. PMID: 31821071 Free PMC article. Clinical Trial.
Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity.
Kawamura T, Imamura CK, Kenmotsu H, Taira T, Omori S, Nakashima K, Wakuda K, Ono A, Naito T, Murakami H, Mushiroda T, Takahashi T, Tanigawara Y. Kawamura T, et al. Among authors: tanigawara y. Cancer Chemother Pharmacol. 2020 Mar;85(3):605-614. doi: 10.1007/s00280-020-04034-y. Epub 2020 Feb 10. Cancer Chemother Pharmacol. 2020. PMID: 32040702
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.
Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, Tanigawara Y, Flockhart DA, Desta Z, Skaar TC, Aki F, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Nakamura Y, Zembutsu H. Kiyotani K, et al. Among authors: tanigawara y. J Clin Oncol. 2010 Mar 10;28(8):1287-93. doi: 10.1200/JCO.2009.25.7246. Epub 2010 Feb 1. J Clin Oncol. 2010. PMID: 20124171 Free PMC article.
Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients.
Kenmotsu H, Imamura CK, Kawamura T, Oyakawa T, Omori S, Nakashima K, Wakuda K, Ono A, Taira T, Naito T, Murakami H, Yamamoto N, Takahashi T, Tanigawara Y. Kenmotsu H, et al. Among authors: tanigawara y. Cancer Chemother Pharmacol. 2022 Aug;90(2):115-123. doi: 10.1007/s00280-022-04452-0. Epub 2022 Jul 12. Cancer Chemother Pharmacol. 2022. PMID: 35821437
165 results